Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 267 results found. Search for [ Pfizer COVID-19 vaccine trials india ]

Results 160 to 180 of 267
BusinessToday.In
November 13, 2020
On nations hoarding vaccine stocks to meet their requirements first, Dmitriev said it is not about vaccine nationalism and that India is an important partner


BusinessToday.In
November 12, 2020
US-based Moderna Inc has claimed that it has sufficient data for a first interim analysis of the advanced-phase trial of its COVID-19 vaccine candidate, which should help ascertain the inoculation's efficacy


Anshula Raj
November 12, 2020
Based on the Phase 2/3 trial results, SII with the help of ICMR will pursue the early availability of this product for India


Rupa Burman Roy
November 11, 2020
In the afternoon session, Sensex and Nifty turned bearish amid high volatility in the domestic market as investors turned cautious ahead of key macro-economic data like CPI and IIP, scheduled to be released tomorrow


BusinessToday.In
November 11, 2020
The AIIMS director said Pfizer's coronavirus vaccine will be difficult to deliver in every corner of the country because of the vaccine's super-cold storage requirement which is not available in most hospitals even in big cities


BusinessToday.In
November 11, 2020
Russia coronavirus vaccine: The interim trial results were announced by Russia's sovereign wealth fund Russian Direct Investment Fund on Wednesday. RDIF is backing the vaccine and marketing it globally


BusinessToday.In
November 11, 2020
COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)


BusinessToday.In
November 11, 2020
More than 43,500 volunteers across 6 countries have participated in the phase-3 trials run jointly by the New York-headquartered pharma giant and the German pharma behemoth BioNTech


BusinessToday.In
November 11, 2020
The major hurdle for the vaccine is storage and distribution. Pfizer's COVID-19 vaccine candidate needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below


BusinessToday.In
November 11, 2020
Coronavirus vaccine: India will focus on these two vaccines as they are being tested on the Indian population and hence has a major advantage over other potential candidates


BusinessToday.In
November 11, 2020
India Stock Market Highlights Today: M&M, followed by Bajaj Finance, Kotak Bank, SBI, ONGC, L&T, Tata Steel, Bajaj Finserv and Maruti were among the top gainers on Sensex pack. On the other hand, IndusInd Bank, HUL, PowerGrid, Titan and Nestle India were among the top losers today


BusinessToday.In
November 10, 2020
The domestic currency opened up at 74.04 per US dollar at the interbank forex market, although, edged slightly lower to 74.05 in early deals, rising 10 paise over its last close


Shailendra Shukla
New Delhi, November 10, 2020
Wipro employees to get single digit pay hike effective December 1 IT major Wipro will offer a single digit salary hike as well as promotions to its high quality performers effective December 1. Pay hike and promotions will be rewarded to employees in bands up to B3 account, who constitute about 80 per cent of the company's total workforce. The company is yet to take a decision on offering salary increments to senior employees above B3 band. Tanishq withdraws another Diwali ad after Twitte...


BusinessToday.In
November 10, 2020
India Stock Market Highlights Today: ICICI Bank followed by ONGC, HDFC, L&T, SBI, HDFC Bank, IndusInd Bank and Bajaj Finance were among the top gainers on Sensex today. On the other hand, Tech Mahindra, Infosys, HCL Tech, TCS, Nestle India and Maruti were in the red


BusinessToday.In
November 10, 2020
Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology, was registered by the Russian Health Ministry


BusinessToday.In
November 7, 2020
India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data


BusinessToday.In
November 4, 2020
COVID-19 vaccine update: Based on the success of the trials and regulatory approvals, we can expect vaccine to be available in India by January 2021, only if its proven immunogenic and efficacious, says SII CEO Adar Poonawalla


BusinessToday.In
November 3, 2020
German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate


Vivek Dubey
October 31, 2020
J&J's COVID-19 vaccine uses a cold virus to deliver coronavirus genetic material to spur an immune response with the help of a platform - called AdVac, also used in the Ebola vaccine


BusinessToday.In
October 29, 2020
Adar Poonawalla claimed there was no immediate concern about the safety of the Oxford vaccine, adding that early indicators have been positive. However, Poonawalla said it will take a year or two to be certain that the vaccine has long-term effect


PAGES 9 OF 14  678910